Kim is Administrative Coordinator at Vivli, where she is responsible for supporting leadership in their day-to-day operations.
Prior to joining Vivli, Kim worked with a commercial real estate firm as an Executive Assistant, supporting a team of brokers and developing standard operating procedures. Kim holds an Associate of Science degree in Public Health.
Bill O’Neil is a Principal Software Engineer at Vivli.
Prior to joining Vivli, Bill worked at Parexel International where he led teams developing and implementing applications for supporting clinical trials, including the management of documents for same. Prior to Parexel Bill was with various commercial ERP software companies developing critical applications for business, including material management for manufacturers, order management, and SharePoint administration.
Irene Troupansky is the Senior Software Architect at Vivli.
Prior to joining Vivli, Irene was a Senior Software Architect at Examity where she helped the company to launch its first Cloud SaaS Multi-Tenant version of Examity Platform and lead its further design and development through the company rapid growing, insuring Examity’s leading place as online proctoring provider. Prior to Examity, Irene was a Lead Architect/Developer at Tracker Systems, where she helped the company to upgrade its product to a Cloud SaaS version and lead the product further design and development.
Azusa joined the Vivli team in 2022 as a Senior Advisor. Azusa will be focusing on clinical data sharing and outreach in Japan. Before joining Vivli, she has nearly 15 years’ experience as leader for the Biostatistics & Programming Department at Sanofi in Tokyo. She holds a degree in algebraic geometry from Tokyo Woman’s Christian University.
Dr. Midega is a Senior Research Manager for Wellcome’s Drug Resistant Infections (DRI) program where she is providing scientific leadership, program development and management support to the surveillance and epidemiology program on Antimicrobial Resistance (AMR). At Wellcome, she led the recently published work on the burden of AMR and continues to lead science and policy research which aims at evaluating how legislative changes banning antibiotic use in animal meat production can reduce the potential transfer of resistant pathogens between animals and humans; and a surveillance program on the development of a comprehensive data capture system for patient-centered AMR surveillance in low- and middle-income countries. In line with the DRI programs interest in accelerating the development of new antibiotics, Janet worked closely with CARB-x based at Boston University, USA in 2018/19, as part of Wellcome’s role as an accelerator and support for companies joining CARBx. Prior to joining Wellcome, Janet was a scientist at Imperial College and the University of Oxford, Big Data Institute; in collaboration with the KEMRI- Wellcome Trust Research Program where she worked for over 10 years conducting academic research on the genomic epidemiology of malaria. Janet is also a Senior Fellow in Public Health at the Aspen Institute, Washington DC, USA.
Dr. Gemma Buckland-Merrett has a PhD in Immunology, an MSc in Global Health and Development and an MSc in Controlling Infectious Diseases. She has spent the last fifteen years working in multi-disciplinary research roles across academic and NGO sectors, bridging the gap between science and policy. Her work has spanned epidemiology, public health and access to medicines research with a particular focus on preventing and controlling infectious diseases and AMR. Prior to joining Wellcome Trust, Gemma was an epidemiologist at Public Health England working on travel-associated infections. She also spent three years working in Africa focusing on evidence-based interventions design to improve access to medicines. Gemma now oversees and leads the DRI work at Wellcome Trust.
Dr. Kajumbula is a Clinical Pathologist specializing in Medical Microbiology since 1998. His area of interest and Research is antimicrobial resistance notably the mechanisms of resistance, molecular approaches to rapid detection resistant infections as well as infection prevention and control. In recognition of his leadership role in the control of antimicrobial resistance in Uganda, Dr Kajumbula was nominated to chair the country’s Antimicrobial Resistance Surveillance Committee, a position he still holds. To this end, he has coordinated development of the Countries National Action Plan against antimicrobial resistance as well as a national surveillance plan for antimicrobial resistance.
Trudie Lang is Professor of Global Health Research; Head of the Global Health Network and Senior Research Scientist in Tropical Medicine, Nuffield Department of Medicine. She has over 20 years’ experience in running clinical trials, including trials in the developing world, for the pharmaceutical industry, the World Health Organisation and in academia.
Trudie focuses on combating diseases of poverty through the generation of high-quality evidence. She has worked in industry, academia and UN organisations. With her team and partners, she works to drive better health outcomes in vulnerable communities by enabling local leadership and ground-up implementation of high-quality health research studies.
Within the University of Oxford, she devised and leads The Global Health Network which is a major international collaborative enterprise that sets out to improve health by improving research.
Dr. Mendelson is chair of the South African Ministerial Advisory Committee on Antimicrobial Resistance (AMR), and a founding, chair of the South African Antibiotic Stewardship Programme. His involvement with international policy related to AMR includes work with the World Health Organization, Global Antibiotic Research & Development Partnership, World Economic Forum, AMR Benchmark, and the Global Health Security Agenda. He is past-president of the Federation of Infectious Diseases Societies of Southern Africa and the International Society for Infectious Diseases.
Dr. Mendelson studied Medicine at St Mary’s Hospital, London, and specialized in infectious diseases at Addenbrookes Hospital, Cambridge, where he attained his PhD. He moved to The Rockefeller University, New York, in 2001 and subsequently to UCT, initially to work on tuberculosis and innate immunity.
Dr. Srinivasan is the Associate Director for Healthcare Associated Infection Prevention Programs in the Division of Healthcare Quality Promotion at the Centers for Disease Control and Prevention. Before coming to CDC he was as Assistant Professor of Medicine in the Infectious Diseases Division at the Johns Hopkins School of Medicine where he was the founding director of the Johns Hopkins Antibiotic Management Program and the associate hospital epidemiologist. His primary responsibilities include oversight and coordination of efforts to eliminate healthcare associated infections and reduce antimicrobial resistance. His research and investigative areas of concentration include outbreak investigations, infection control, multi-drug resistant gram negative pathogens and antimicrobial use. Dr. Srinivasan has published more than 100 articles in peer-reviewed journals on his research in healthcare epidemiology, infection control and antimicrobial use and resistance. He continues to attend clinically on the infectious diseases consultation service at the Atlanta Veteran’s Affairs hospital.